Thus, we assumed that NDGA, LPL inhibitor-mediated hypertriglyceridemia, hypercholesterolemia, hypoadiponetimia, and hyperglycemia are compensated due to the action of hepatic lipid homeostasis caused by LPL. The gene discussed is LPL; the disease is Hypercholesterolemia.